查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1530330

全球无菌注射 CDMO 市场：市场规模、份额和趋势分析 - 按分子、按产品、按服务、按治疗领域、按给药途径、按最终用途、按地区、细分市场预测，2024-2030 年

Sterile Injectables CDMO Market Size, Share & Trends Analysis Report By Molecule (Small Molecule, Large Molecule), By Product, By Service, By Therapeutic Area, By Route of Administration, By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

预计2023年全球无菌注射CDMO市场规模将达39.4亿美元，2024年至2030年复合年增长率为9.92%。

市场成长主要是由于注射药物的管道和核准的增加。製药公司正在积极致力于开发注射药物，这种药物具有许多优势，包括起效更快、剂量更精确以及提高患者依从性。例如，根据美国食品药物管理局（FDA）2024年1月发布的报告，药物评估与研究中心（CDER）在2023年核准了55种新药。这些药物还包括注射剂，显示产品线很强大。该管道预计将推动商业和研究目的契约製造服务的需求增加，从而促进整体市场的成长。

对细胞和基因治疗的需求不断增长正在推动市场成长。随着治疗产品线的扩大，对受託製造厂商(CMO) 提供的专业製造能力的需求也在增加。例如，根据 ClinicalTrials.gov 的数据，截至 2024 年 3 月，北美有超过 581 项临床试验专注于细胞疗法和治疗各种疾病的相关方法，预计在整个预测期内契约製造将会增加。

此外，市场参与企业的策略性倡议，例如扩大无菌生产设施和协作研究/伙伴关係，预计将在整个预测期内促进市场成长。例如，2023年11月，NorthEdge将投资Torbay Pharmaceuticals，以支持未来的国际扩张。 2023 年 3 月，PCI Pharma Services 宣布对其伊利诺州罗克福德工厂进行 5,000 万美元的扩建计划。该计划将包括建造一座 20 万平方英尺的新大楼，以提高注射药物和器械组合产品的生产能力。

对无菌注射剂的高需求正在推动契约製造製造商和生物製药公司之间委託协议的成长，从而推动无菌注射剂 CDMO 行业的成长。对快速药效、快速吸收和较低药物浓度的需求不断增长，是推动无菌注射 CDMO 行业采用的一些关键方面。此外，积极参与无菌注射剂开发和製造的製药公司也越来越多地支持单株抗体疗法、大分子注射剂和感染疾病治疗药物。有几个因素正在加速全球市场上无菌注射 CDMO 的成长，包括研发週期缩短时间、非专利药注射成本降低以及罕见疾病治疗的进步。

此外，先进的製造技术对于确保抗癌药物的稳定性和功效至关重要。专门从事无菌注射剂的契约製造製造商，特别是那些在复杂配方和生技药品方面拥有丰富经验的製造商，有能力满足癌症药物的独特要求。无菌注射剂对于在癌症治疗中提供复杂的生技药品和创新治疗方法至关重要，并且正在推动无菌注射契约製造製造业的成长。预计外包的成长将在预测期内推动该产业的扩张。製药公司，特别是专注于肿瘤学的製药公司，越来越多地转向外包製造业务，以简化流程、降低成本并利用製造外包提供的专业知识。这一转变极大地促进了癌症领域无菌注射药物的合约开发和受託製造市场。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章 无菌注射 CDMO 市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
  • 技术进步
  • 定价模式分析
  • 临床试验定量分析，2023
  • 无菌注射 CDMO 市场：分析工具
  • COVID-19 影响分析

第 4 章 无菌注射 CDMO 市场：分子估计与趋势分析

  • 细分仪表板
  • 全球无菌注射CDMO市场波动分析
  • 2018-2030年全球无菌注射CDMO市场规模及趋势分析（依分子）
  • 低分子
  • 聚合物

第五章无菌注射 CDMO 市场：产品估算与趋势分析

  • 细分仪表板
  • 全球无菌注射CDMO市场波动分析
  • 2018-2030年全球无菌注射CDMO市场规模及趋势分析（依产品）
  • 无菌注射液
  • 预填充式注射器
  • 管瓶/安瓿

第六章无菌注射 CDMO 市场：服务评估与趋势分析

  • 细分仪表板
  • 全球无菌注射CDMO市场波动分析
  • 2018-2030年全球无菌注射CDMO市场规模及趋势分析（依服务）
  • 合约开发
  • 契约製造
  • 包装
  • 品管/保证
  • 冷冻干燥服务

第七章无菌注射CDMO市场：治疗领域的估算与趋势分析

  • 细分仪表板
  • 全球无菌注射CDMO市场波动分析
  • 2018-2030年全球无菌注射CDMO市场规模及趋势分析、治疗领域
  • 肿瘤学
  • 循环系统疾病
  • 法律代表
  • 中枢神经系统疾病
  • 感染疾病
  • 肌肉骨骼疾病
  • 荷尔蒙疾病
  • 其他的

第八章无菌注射CDMO市场：给药途径预估及趋势分析

  • 细分仪表板
  • 全球无菌注射CDMO市场波动分析
  • 2018-2030年全球无菌注射CDMO市场规模及趋势分析、给药途径
  • 皮下注射（SC）
  • 静脉注射 (IV)
  • 肌肉注射 (IM)
  • 其他的

第 9 章 无菌注射 CDMO 市场：最终用途估计与趋势分析

  • 细分仪表板
  • 全球无菌注射CDMO市场波动分析
  • 2018-2030年全球无菌注射CDMO市场规模与趋势分析、最终用途
  • 製药公司
  • 生物製药公司
  • 其他的

第10章无菌注射CDMO市场：区域估计与趋势分析

  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 2018-2030 年北美市场估计与预测
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030 年欧洲市场估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030 年亚太市场估计与预测
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 2018-2030 年拉丁美洲市场估计与预测
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 2018-2030 年中东和非洲市场估计和预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十一章竞争格局

  • 市场参与企业分类
    • 市场领导
    • 新兴玩家
  • 服务热图分析
  • 公司简介
    • Boehringer Ingelheim GmbH
    • Boehringer Ingelheim GmbH
    • Vetter Pharma
    • Recipharm AB
    • Aenova Group
    • Fresenius Kabi
    • Famar
    • NextPharma Technologies
    • Ajinomoto Bio-Pharma Services
    • PCI Pharma Services
    • IDT Biologika
    • Alcami Corporation
    • Fareva Group
    • Eurofins CDMO
    • Siegfried Holding AG
Product Code: GVR-4-68040-363-5

Sterile Injectables CDMO Market Trends

The global sterile injectables CDMO market size was estimated at USD 3.94 billion in 2023 and is projected to grow at a CAGR of 9.92% from 2024 to 2030. The market growth is primarily driven by increasing pipeline and approvals of injectable drugs. Pharmaceutical companies are proactively focusing on developing injectable medications due to their numerous benefits, such as quicker onset of action, precise dosing, and enhanced patient adherence. For instance, as per the U.S. Food and Drug Administration (FDA) report published in January 2024, the Center for Drug Evaluation and Research (CDER) approved 55 novel drugs in 2023. These medications included injectables, indicating a robust pipeline that is anticipated to drive an increase in the demand for contract manufacturing services for both commercial and research purposes, hence contributing to overall market growth.

The increasing demand for cellular and genetic therapies is driving the market's growth. With the expansion of therapy pipelines, there is a rising requirement for specialized manufacturing capabilities provided by contract manufacturing organizations (CMOs). For instance, according to ClinicalTrials.gov, as of March 2024, over 581 clinical trials were focused on cell therapies and related approaches for treating various diseases in North America is anticipated to drive an increase in contract manufacturing throughout the projected period.

Furthermore, strategic initiatives undertaken by market participants, such as expanding sterile manufacturing facilities and engaging in collaborations and partnerships, are anticipated to bolster market growth throughout the projected period. For instance, in November 2023, NorthEdge invested in Torbay Pharmaceuticals to support its upcoming phase of international expansion. In March 2023, PCI Pharma Services has announced a USD 50 million expansion project at its Rockford, Illinois facility, which will involve the construction of a new 200,000-square-foot building to increase the site's capacity for manufacturing injectable drug-device combination products.

The high demand for sterile injectables propels growth in outsourced agreements amongst contract manufacturers and biopharmaceutical companies, thereby boosting the growth of the sterile injectable CDMO industry. The growing need for faster drug action, rapid absorption, and less drug concentration are a few major aspects contributing to the adoption of sterile injectables CDMO industry. Further, pharmaceutical firms actively involved in sterile injectable development and manufacturing are gaining traction to support monoclonal antibody therapies, large-molecule injectable drugs, and infectious disease-treating drugs. Several factors, including reduced time and cost-affordable research and development cycles of generic injectables and the growing advancements in rare disease treatments, are accelerating the growth of sterile injectable CDMO's in the global market.

Moreover, advanced manufacturing techniques are crucial for ensuring the stability and efficacy of cancer therapies. Contract manufacturers specializing in sterile injectables, particularly those experienced in handling complex formulations and biologics, are well-equipped to address the specific requirements of oncology drugs. Sterile injectables are essential for delivering complex biologics and innovative treatment methods in cancer treatment, driving the growth of the sterile injectable contract manufacturing sector. The growth in outsourcing practices is expected to drive the expansion of the segment over the forecast period. Pharmaceutical companies, particularly those specializing in oncology, are increasingly turning to outsourcing manufacturing operations to streamline processes, cut costs, and capitalize on the specialized expertise offered by contract manufacturers. This shift has notably boosted the cancer sector's sterile injectable contract development and manufacturing market.

Global Sterile Injectables CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global Sterile Injectables CDMO market report based on molecule type, product, service, therapeutic area, route of administration, end use, and region:

  • Molecule Outlook (Revenue, USD Million, 2018 - 2030)
  • Small Molecule
  • Large Molecule
  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Sterile Liquid Injectables
  • Pre-filled Syringes
  • Vials and Ampoules
  • Service Outlook (Revenue, USD Million, 2018 - 2030)
  • Contract Development
  • Contract Manufacturing
  • Packaging
  • Quality Control and Assurance
  • Lyophilization Services
  • Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
  • Oncology
  • Cardiovascular Diseases
  • Central Nervous System Diseases
  • Infectious Disorders
  • Musculoskeletal Diseases
  • Hormonal Diseases
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
  • Subcutaneous (SC)
  • Intravenous (IV)
  • Intramuscular (IM)
  • Others
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

China

Japan

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa (MEA)

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Sterile Injectables CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Pipeline and Approvals of Injectables
      • 3.2.1.2. Growing Demand for Biologics and Biosimilars Significantly Supported Market Growth
      • 3.2.1.3. Rise in Investment Across Research & Development Activities for the Development of Novel Therapeutics
      • 3.2.1.4. Increasing Demand for Cell & Gene Therapies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Low Barriers to Market Penetration Have Resulted in Pricing Pressure
      • 3.2.2.2. Challenges Related to Quality Control
  • 3.3. Technological Advancements
  • 3.4. Pricing Model Analysis
  • 3.5. Clinical Trials Volume Analysis, 2023
    • 3.5.1. Total Number of Clinical Trials, by Region (2023)
    • 3.5.2. Total Number of Clinical Trials, by Phase (2023)
    • 3.5.3. Total Number of Clinical Trials, by Study Design (2023)
    • 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
  • 3.6. Sterile Injectables CDMO Market: Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Sterile Injectables CDMO Market: Molecule Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 4.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Molecule, 2018 to 2030 (USD Million)
  • 4.4. Small Molecule
    • 4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Sterile Injectables CDMO Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 5.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 5.4. Sterile Liquid Injectables
    • 5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.5. Pre-filled Syringes
    • 5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.6. Vials and Ampoules
    • 5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Sterile Injectables CDMO Market: Service Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 6.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 6.4. Contract Development
    • 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.5. Contract Manufacturing
    • 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.6. Packaging
    • 6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.7. Quality Control and Assurance
    • 6.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.8. Lyophilization Services
    • 6.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Sterile Injectables CDMO Market: Therapeutic Area Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 7.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, Therapeutic Area, 2018 to 2030 (USD Million)
  • 7.4. Oncology
    • 7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.5. Cardiovascular Diseases
    • 7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.6. Legal Representation
    • 7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.7. Central Nervous System Diseases
    • 7.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.8. Infectious Disorders
    • 7.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.9. Musculoskeletal Diseases
    • 7.9.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.10. Hormonal Diseases
    • 7.10.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.11. Others
    • 7.11.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Sterile Injectables CDMO Market: Route of Administration Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 8.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, Route of Administration, 2018 to 2030 (USD Million)
  • 8.4. Subcutaneous (SC)
    • 8.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5. Intravenous (IV)
    • 8.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6. Intramuscular (IM)
    • 8.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.7. Others
    • 8.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 9. Sterile Injectables CDMO Market: Modality by End Use Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 9.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, End Use, 2018 to 2030 (USD Million)
  • 9.4. Pharmaceutical Companies
    • 9.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 9.5. Biopharmaceutical Companies
    • 9.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 9.6. Others
    • 9.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 10. Sterile Injectables CDMO Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Dashboard
  • 10.2. Global Regional Market Snapshot
  • 10.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.4. North America
    • 10.4.1. North America Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Scenario
      • 10.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Scenario
      • 10.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Scenario
      • 10.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.5. Europe
    • 10.5.1. Europe Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.2. UK
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Competitive Scenario
      • 10.5.2.3. Regulatory Scenario
      • 10.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.3. Germany
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Competitive Scenario
      • 10.5.3.3. Regulatory Scenario
      • 10.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.4. France
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Competitive Scenario
      • 10.5.4.3. Regulatory Scenario
      • 10.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.5. Italy
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Competitive Scenario
      • 10.5.5.3. Regulatory Scenario
      • 10.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.6. Spain
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Competitive Scenario
      • 10.5.6.3. Regulatory Scenario
      • 10.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.7. Denmark
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Competitive Scenario
      • 10.5.7.3. Regulatory Scenario
      • 10.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.8. Sweden
      • 10.5.8.1. Key Country Dynamics
      • 10.5.8.2. Competitive Scenario
      • 10.5.8.3. Regulatory Scenario
      • 10.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.9. Norway
      • 10.5.9.1. Key Country Dynamics
      • 10.5.9.2. Competitive Scenario
      • 10.5.9.3. Regulatory Scenario
      • 10.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.6. Asia Pacific
    • 10.6.1. Asia Pacific Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.2. China
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Scenario
      • 10.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.3. Japan
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Scenario
      • 10.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.4. India
      • 10.6.4.1. Key Country Dynamics
      • 10.6.4.2. Competitive Scenario
      • 10.6.4.3. Regulatory Scenario
      • 10.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.5. Australia
      • 10.6.5.1. Key Country Dynamics
      • 10.6.5.2. Competitive Scenario
      • 10.6.5.3. Regulatory Scenario
      • 10.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.6. South Korea
      • 10.6.6.1. Key Country Dynamics
      • 10.6.6.2. Competitive Scenario
      • 10.6.6.3. Regulatory Scenario
      • 10.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.7. Thailand
      • 10.6.7.1. Key Country Dynamics
      • 10.6.7.2. Competitive Scenario
      • 10.6.7.3. Regulatory Scenario
      • 10.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.7. Latin America
    • 10.7.1. Latin America Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.2. Brazil
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Scenario
      • 10.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.3. Argentina
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Scenario
      • 10.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.8. MEA
    • 10.8.1. MEA Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.2. South Africa
      • 10.8.2.1. Key Country Dynamics
      • 10.8.2.2. Competitive Scenario
      • 10.8.2.3. Regulatory Scenario
      • 10.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.3. Saudi Arabia
      • 10.8.3.1. Key Country Dynamics
      • 10.8.3.2. Competitive Scenario
      • 10.8.3.3. Regulatory Scenario
      • 10.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.4. UAE
      • 10.8.4.1. Key Country Dynamics
      • 10.8.4.2. Competitive Scenario
      • 10.8.4.3. Regulatory Scenario
      • 10.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.5. Kuwait
      • 10.8.5.1. Key Country Dynamics
      • 10.8.5.2. Competitive Scenario
      • 10.8.5.3. Regulatory Scenario
      • 10.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Market Participant Categorization
    • 11.1.1. Market Leaders
    • 11.1.2. Emerging Players
  • 11.2. Service Heat Map Analysis (a comparative analysis of the players together)
  • 11.3. Company Profiles
    • 11.3.1. Boehringer Ingelheim GmbH
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. Boehringer Ingelheim GmbH
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. Vetter Pharma
      • 11.3.3.1. Company Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Recipharm AB
      • 11.3.4.1. Company Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. Aenova Group
      • 11.3.5.1. Company Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. Fresenius Kabi
      • 11.3.6.1. Company Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. Famar
      • 11.3.7.1. Company Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. NextPharma Technologies
      • 11.3.8.1. Company Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. Ajinomoto Bio-Pharma Services
      • 11.3.9.1. Company Overview
      • 11.3.9.2. Financial Performance
      • 11.3.9.3. Service Benchmarking
      • 11.3.9.4. Strategic Initiatives
    • 11.3.10. PCI Pharma Services
      • 11.3.10.1. Company Overview
      • 11.3.10.2. Financial Performance
      • 11.3.10.3. Service Benchmarking
      • 11.3.10.4. Strategic Initiatives
    • 11.3.11. IDT Biologika
      • 11.3.11.1. Company Overview
      • 11.3.11.2. Financial Performance
      • 11.3.11.3. Service Benchmarking
      • 11.3.11.4. Strategic Initiatives
    • 11.3.12. Alcami Corporation
      • 11.3.12.1. Company Overview
      • 11.3.12.2. Financial Performance
      • 11.3.12.3. Service Benchmarking
      • 11.3.12.4. Strategic Initiatives
    • 11.3.13. Fareva Group
      • 11.3.13.1. Company Overview
      • 11.3.13.2. Financial Performance
      • 11.3.13.3. Service Benchmarking
      • 11.3.13.4. Strategic Initiatives
    • 11.3.14. Eurofins CDMO
      • 11.3.14.1. Company Overview
      • 11.3.14.2. Financial Performance
      • 11.3.14.3. Service Benchmarking
      • 11.3.14.4. Strategic Initiatives
    • 11.3.15. Siegfried Holding AG
      • 11.3.15.1. Company Overview
      • 11.3.15.2. Financial Performance
      • 11.3.15.3. Service Benchmarking
      • 11.3.15.4. Strategic Initiatives

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Sterile Injectables CDMO, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Sterile Injectables CDMO, for Small Molecule, 2018 - 2030 (USD Million)
  • Fig. 13 Global Sterile Injectables CDMO, for Large Molecule, 2018 - 2030 (USD Million)
  • Fig. 14 Global Sterile Injectables CDMO, for Sterile Liquid Injectables, 2018 - 2030 (USD Million)
  • Fig. 15 Global Sterile Injectables CDMO, for Pre-filled Syringes, 2018 - 2030 (USD Million)
  • Fig. 16 Global Sterile Injectables CDMO, for Vials and Ampoules, 2018 - 2030 (USD Million)
  • Fig. 17 Global Sterile Injectables CDMO, for Contract Development, 2018 - 2030 (USD Million)
  • Fig. 18 Global Sterile Injectables CDMO, for Contract Manufacturing, 2018 - 2030 (USD Million)
  • Fig. 19 Global Sterile Injectables CDMO, for Packaging, 2018 - 2030 (USD Million)
  • Fig. 20 Global Sterile Injectables CDMO, for Quality Control and Assurance, 2018 - 2030 (USD Million)
  • Fig. 21 Global Sterile Injectables CDMO, for Lyophilization Services, 2018 - 2030 (USD Million)
  • Fig. 22 Global Sterile Injectables CDMO, for Oncology, 2018 - 2030 (USD Million)
  • Fig. 23 Global Sterile Injectables CDMO, for Central Nervous System Diseases, 2018 - 2030 (USD Million)
  • Fig. 24 Global Sterile Injectables CDMO, for Infectious Disorders, 2018 - 2030 (USD Million)
  • Fig. 25 Global Sterile Injectables CDMO, for Musculoskeletal Diseases, 2018 - 2030 (USD Million)
  • Fig. 26 Global Sterile Injectables CDMO, for Others, 2018 - 2030 (USD Million)
  • Fig. 27 Global Sterile Injectables CDMO, for Subcutaneous (SC), 2018 - 2030 (USD Million)
  • Fig. 28 Global Sterile Injectables CDMO, for Intravenous (IV), 2018 - 2030 (USD Million)
  • Fig. 29 Global Sterile Injectables CDMO, for Intramuscular (IM), 2018 - 2030 (USD Million)
  • Fig. 30 Global Sterile Injectables CDMO, for Others, 2018 - 2030 (USD Million)
  • Fig. 31 Global Sterile Injectables CDMO, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 32 Global Sterile Injectables CDMO, for Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 33 Global Sterile Injectables CDMO, for Others, 2018 - 2030 (USD Million)
  • Fig. 34 Regional Outlook, 2023 & 2030
  • Fig. 35 North America Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Canada Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Europe Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 UK Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 France Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Italy Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Spain Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Norway Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Asia Pacific Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Japan Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 China Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 India Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Australia Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Korea Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Thailand Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Latin America Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Brazil Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 UAE Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)